| Autor: |
Nasr, Sonia Ben, Balti, Mehdi, Mansour, Hajer Ben, Zribi, Aref, Ayari, Jihen, Fendri, Sana, Msakni, Issam, Bougrine, Fathi, Bouziani, Ammar, Haddaoui, Abderrazek |
| Předmět: |
|
| Zdroj: |
Pan Arab Journal of Oncology; Sep2016, Vol. 9 Issue 3, p31-34, 4p |
| Abstrakt: |
Introduction: HER 2 Overexpression in breast cancer has prognostic value and predictive value of treatment response. The aim of our study was to evaluate immunohistochemistry (IHC) and chromogenic in situ hybridization technique (CISH) to assess HER 2 expression in breast cancer. Methods: We conducted a retrospective study on 50 immunohistochemical tests in Anatomy and Cytology department of the Military Hospital of Tunis between November 2003 and July 2009. Results: Average age was 48.5 years (32 80 years). Average tumor size was 32 mm (15 and 90 mm). It was more than 3 cm in 52% of cases. The infiltrating ductal carcinoma accounted for 94% of cases. Forty-four percent of cases were grade histoprognostic Scarff-Bloom-Richardson (SBR) III or II. Sixty percent of our patients had lymph node metastases at diagnosis. One-third of breast cancers had more than 5 lymph nodes at diagnosis. IHC has concluded to the overexpression of HER-2 in 18% of cases. Ten breast cancers score 2 + required further exploration by CISH. Three of these have overerexpressed HER 2 with CISH technique. Thus, overexpression of HER 2 was obtained in 24% of cases when we associated CISH to IHC. We did not find any relationship between the overexpression of HER-2 and age, tumor size, lymph node involvement, SBR score and hormone receptors. Conclusion: IHC is the method of choice for the determination of HER2 status in breast cancer. It s a reliable, rapid and inexpensive method. It can be standardized and calibrated taking FISH or CISH as a technical reference. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
